Radiation sterilization has new and updated methods for conducting terminal sterilization validations on devices intended to be exposed to either gamma or electron beam irradiation processes. For example, flexibility of the minimum terminal sterilization dose can now be determined based on a product’s microbial population (bioburden).
NAMSA invites you to join us on July 26, 2018 (10-11 AM ET) as Ed Arscott, Senior Product Development Strategist, discusses the following:
Time will also be allotted for Q&A.
*By registering for this event, you are providing NAMSA consent to contact you directly regarding NAMSA’s services. The information you are providing will be processed by NAMSA to better understand your product needs and interests.
About the Presenter:
Ed Arscott, NAMSA Senior Product Development Strategist
Ed Arscott has been with NAMSA for over 17 years in total, with 12 years at NAMSA’s Toledo, Ohio Microbiology Lab. He currently serves as a Senior Product Development Strategist. Prior to returning to NAMSA, Ed spent 14 years at DePuy Orthopedics as the WW Manager of Microbiology and was responsible for all aspects of the company’s sterilization and microbiology-related activities for four manufacturing facilities. Mr. Arscott has a deep understanding of all routine sterilization modalities along with novel sterilization technologies, and is experienced in the areas of biological indicators and medical microbiology pertaining to antimicrobial testing. He holds two method patents on antimicrobial delivery systems, in addition to a Bachelor of Science degree in Applied Microbiology from Bowling Green State University.